The Centers for Medicare & Medicaid Services Jan. 26 released proposed changes to Medicare Advantage plan capitation rates and Part D payment policies for calendar year 2027, which the agency estimates will result in a net average year-over-year increase of 0.09% in MA plan payments, or $700 million. CMS proposes to address coding differences between MA and Original Medicare, in addition to updating the MA risk adjustment model to reflect current costs associated with various conditions and characteristics. The agency also proposes to exclude diagnosis information from unlinked chart review records from risk score calculation in CY 2027 and solicits feedback on new measures that would incentivize plans from providing unnecessary, inappropriate or low-value care, as well as measures related to medical errors or misdiagnoses. CMS also plans updates to the Part D risk adjustment model. Out-of-pocket prescription drug costs for individuals with Medicare Part D are proposed to be capped at $2,400 in 2027, up from $2,100 in 2026. Comments on the CY 2027 proposals are due Feb. 25. The agency expects to publish a final rate announcement on or before April 6. 

Perspective
Public
Approximately 35 million Americans are enrolled in Medicare Advantage plans in 2026, and that number is expected to grow to about 45 million MA enrollees by…
Headline
The Centers for Medicare & Medicaid Services has released details on downloading its upcoming fiscal year 2025 Program for Evaluating Payment Patterns…
Headline
The Department of Health and Human Services Administration for Community Living has launched the first phase of its Health at Home Challenge, a competition to…
Headline
The AHA shared the following statement with the media in response to a report released May 7 by Families USA.   “This report is long on rhetoric and…
Headline
The AHA May 7 wrote to House and Senate lawmakers in support of the Medicare Advantage Improvement Act (H.R. 8375/S. 4384), bipartisan and bicameral…
Headline
The Centers for Medicare & Medicaid Services announced May 6 that it will provide access to certain glucagon-like peptide-1 (GLP-1) medications to eligible…